The Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain.

Remidio’s Medios HI AI tools for glaucoma and AMD receives CDSCO approval: Our Bureau, Mumbai Wednesday, May 7, 2025, 15:30 Hrs [IST] Remidio Innovative Solutions Pvt. Ltd., a l ...

Q1 2025 Earnings Call Transcript May 6, 2025 Krystal Biotech, Inc. misses on earnings expectations. Reported EPS is $1.2 EPS, expectations were $1.38. Operator: Thank you for standing by, and welcome ...

Learn about eye changes that could indicate serious health conditions, from blurry vision to persistent floaters and flashes ...

First came what Jade O'Saye thought was a stye then pain when she blinked. Within months, her right eye was so swollen and ...

If you find that whenever you walk out into sunlight, you sneeze, you may be part of around 25% of the population who have a ...

Thank you for standing by, and welcome to the Krystal Biotech First Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode. After the speakers' presentations, there will ...

US FDA grants fast track designation to OKYO Pharma’s urcosimod to treat neuropathic corneal pain: London Saturday, May 3, 2025, 17:00 Hrs [IST] OKYO Pharma Limited, an ophthalm ...

State FDA, Karnataka, clears Medios HI Glaucoma AI and Medios HI AMD AI for nationwide use, expanding access to early ...

Headache and ocular pain are frequent complaints in ophthalmic practice ... and headaches associated with other cranial nerve involvement. Intraocular findings may be manifestations of both ...

Have you ever ridden a horse in a bitless bridle and would you consider doing so if you don’t already? Few things cause more ...

SALT LAKE CITY — Multimodal AI models may be useful to predict glaucomatous status of eyes, according to a poster presentation at the Association for Research in Vision and Ophthalmology meeting ...